Rezolute (RZLT) Stock Forecast & Price Target

Rezolute is positioned favorably because FDA feedback after reviewing Phase 3 sunRIZE data and recommending a pre-BLA meeting suggests a credible regulatory path for ersodetug in congenital hyperinsulinism, without an immediate request for another clinical trial. The clinical package is reinforced by sustained glycemic benefit in the open-label extension, with 59 sunRIZE completers entering extension and 56 still on treatment, alongside meaningful reductions in hypoglycemia events and background standard-of-care use. Confidence also rises in tumor-associated hyperinsulinism, where upLIFT has seven responders among the first eight patients and the objective IV glucose endpoint appears less vulnerable to behavioral confounding, supporting the case for approval potential across both indications.

Rezolute is fundamentally challenged by outsized clinical and regulatory risk, because its lead asset Ersodetug must still prove durable efficacy and tolerability while also clearing potential FDA requirements for additional studies or rejection. The commercial opportunity is also constrained by congenital hyperinsulinism being an ultra-orphan market with existing treatments and the threat of better competing therapies, which could limit adoption even if the drug succeeds. Financially, the company remains unprofitable, reported a 4Q26 loss per share of $0.20 versus a $0.12 estimate, and despite $107.8M in cash and investments expected to fund at least 12 months, higher G&A tied to commercialization and a history of losses heighten dilution and execution risk.